Search | Page 9 | AMCP Learn

(L2) Federal Legislative and Regulatory Update - Nexus 2026
(M2) Development of High-Impact Algorithms: Unlocking U.S. Payer Data to Improve Patient Outcomes
(R2) Repositioning of Biosimilars: How Can the U.S. Optimize Biosimilar Utilization to Improve Patient Health and Lower Total Cost of Care
(W2) AI in Managed Care Pharmacy: Opportunities, Risks, and Readiness for Decision‑Makers Making the Way for Innovation
(D3) Rare Disease Spotlight: Disease Burden, Unmet Needs, and Amplifying the Patient Voice, Managed Care Insights into Cushing’s Syndrome
(M3) Beyond Drug Cost: The Models, Tradeoffs, and Decisions Behind Coverage
(R3) Practice Over Promise: Payment and Coverage Access to Precision Medicine Through a Real-World Lens
(K1) America's Next Top Model?
(D4) A Clinical Update on Secondary Cardiovascular Disease Risk Factors and Risk Management
(F4) Precision at Scale: Translating the Evolving Biomarker Landscape in NSCLC Into Strategies for Timely and Targeted Care
(L4) Beyond Price Negotiation: Has Maximum Fair Price (MFP) Reshaped Formulary Dynamics?
(M4) Beyond Strategy: Addressing Drivers of Health Through Pharmacy Operations
(R4) Payer Evidence and Decision-Making in Rare vs. Common Disease Products
(D5) Integrating Perimenopause and Menopause Care into the Pharmacy Benefit: A Managed Care Framework for Improving Women’s Heal
(F5) Ahead of the Curve: Emerging Specialty Therapies and Managed Care Readiness
(L5) The Commissioner's National Priority Voucher (CNPV) Pilot One Year Later: Real-World Approvals and Managed Care Impact
(R5) The Intersection of Population Health and Managed Care Pharmacy: Building Programs That Measure What Matters
(W5) Human Intelligence in the Age of AI: Ensuring Trust and Rigor across Real-World Evidence Lifecycle
(D6) Mind the Gap: Bridging Pharmacy and Medical Benefits to Optimize Biosimilar Value
(M6) The New Economics of Health Plan Pharmacy
(R6) From Pipeline to Patient: Navigating the Next Wave of Cell & Gene Therapies
(K2) The AI Debate: Advancing Humanity or Undermining It?
(K3) Oncology Pipeline 2026: Advances, Trends, and Impact
Examining the Current and Future State of Hemophilia B Gene Therapy in Managed Care

Pages